中西医结合肝病杂志2025，Vol.35Issue(10)：1227-1231,5.DOI:10.3969/j.issn.1005-0264.2025.010.008
TACE联合靶向药物与免疫检查点抑制剂治疗对肝癌中晚期患者的疗效及生存时间的影响
The efficacy of TACE combined with targeted drugs and immune checkp-oint inhibitors in the treatment of advanced liver cancer patients and their impact on survival time
摘要
Abstract
Objective:Exploring the efficacy of hepatic artery chemoembolization(TACE)combined with targeted drugs and immune checkpoint inhibitors in the treatment of patients with advanced liver cancer and its impact on their survival time.Methods:A retrospective study was conducted on the clinical data of 150 patients with advanced liver cancer admitted to our hospital from March 2019 to March 2023.According to different treatment methods,they were divided into a TACE+targeted drug+immune checkpoint inhibitor group of 96 cases and a TACE+targeted drug group of 54 cases.Compare the differences in efficacy,serum tumor markers,vascular endothelial indicators,incidence of adverse reactions,and survival status between two groups.Results:Rank sum test of rank data showed that compared to the TACE+targeted drug group,the TACE+targeted drug+immune checkpoint inhibitor group had better DCR and ORR rates(P<0.05).Compared to before treatment,the levels of CA199,AFP,and CEA in both groups decreased after treatment(P<0.05).And the research group was lower than the control group(P<0.05).Compared to before treatment,the levels of GGT,PDGF,and VEGF in both groups decreased after treatment(P<0.05);And the levels of CA199,AFP and CEA in the study group after treatment were lower than those in the control group(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).As of March 2024,the follow-up period was 12-60 months.In the TACE+targeted drugs+immune checkpoint inhibitors group,32 cases(33.33%)survived,with a survival time of(23.16±5.32)months;Eight cases(14.81%)survived in the TACE+targeted drug group,with a survival time of(19.41±6.18)months;There was a statistically significant difference in survival time and survival rate between the two groups(P<0.05).The overall survival of the TACE+targeted drug+immune checkpoint inhibitor group was better than that of the TACE+targeted drug group,and the differences were statistically significant(χ2=16.139,P<0.05).Conclusion:TACE+targeted drugs+immune checkpoint inhibitors have good therapeutic effects on patients with advanced liver cancer,which can effectively reduce the levels of serum tumor markers and vascular endothelial indicators,improve survival status,and do not increase the incidence of adverse reactions.关键词
肝癌/中晚期/肝动脉化疗栓塞术/靶向药物/免疫检查点抑制剂/疗效/生存时间Key words
liver cancer/middle to late stage/hepatic artery chemoembolization/targeted drugs/immune checkpoint inhibitors/therapeutic effect/survival time分类
医药卫生引用本文复制引用
曾源,杨双,杨浩..TACE联合靶向药物与免疫检查点抑制剂治疗对肝癌中晚期患者的疗效及生存时间的影响[J].中西医结合肝病杂志,2025,35(10):1227-1231,5.基金项目
四川省医学青年创新科研课题计划(No.Q20074) （No.Q20074）
